RT Book, Section
A1 Tfayli, Arafat
A1 Kojouri, Kiarash
A1 George, James N.
A2 Boyiadzis, Michael M.
A2 Frame, James N.
A2 Kohler, David R.
A2 Fojo, Tito
SR Print(0)
ID 1128368349
T1 Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome
T2 Hematology-Oncology Therapy, 2e
YR 2016
FD 2016
PB McGraw-Hill Education
PP New York, NY
SN 9780071637893
LK hemonc.mhmedical.com/content.aspx?aid=1128368349
RD 2024/04/16
AB Thrombotic  thrombocytopenic  purpura  (TTP)  is  defined  clinically  by  the  abnormalities  caused  by  systemic  thrombotic  microangiopathy:  thrombocytopenia  and  microangiopathic  hemolytic  anemia.  Additional  clinical  features  may  include  neurologic  abnormalities,  renal  failure,  and  gastrointestinal  symptoms  Hemolytic-uremic  syndrome  (HUS)  is  another  clinical  presentation  of  thrombotic  microangiopathy.  Like  TTP,  HUS  is  manifested  by  thrombocytopenia  and  microangiopathic  hemolytic  anemia  with  the  additional  abnormality  of  renal  failure.  Although  it  is  commonly  stated  that  HUS  is  manifested  primarily  by  renal  failure  whereas  TTP  is  manifested  primarily  by  neurologic  abnormalities,  these  2  syndromes  cannot  be  distinguished  clinically,  because  many  patients  have  both  renal  failure  and  severe  neurologic  abnormalities,  or  neither.  The  term  HUS  is  often  restricted  to  children.  In  adults,  all  syndromes  are  referred  to  as  TTP,  whether  or  not  neurologic  abnormalities  or  renal  failure  are  present  Amorosi  EL,  Ultmann  JE.  Medicine  (Baltimore)  1966;45:139–159George  JN.  N  Engl  J  Med  2006;354:1927–1935